Retatrutide produces substantial weight loss in phase 3 diabetes trial

TRIUMPH-2, a phase 3 randomised placebo-controlled trial, evaluated once-weekly retatrutide (a GIP, GLP-1, and glucagon receptor agonist) in 1152 adults with obesity and type 2 diabetes over 80 weeks. The trial reported mean bodyweight reductions of 11.9%, 16.8%, and 18.8% with retatrutide 4 mg, 9 mg, and 12 mg respectively, versus 5.1% with placebo, with gastrointestinal adverse events (diarrhoea, nausea) and higher rates of hypotension, dysesthesia, and treatment discontinuation occurring more frequently in retatrutide groups than placebo. The authors state the safety profile was generally consistent with other GLP-1 receptor agonist molecules and that retatrutide might be effective for obesity treatment in people with type 2 diabetes.

Most relevant for: Adults with obesity and type 2 diabetes already on stable oral glucose-lowering therapy who have had prior unsuccessful weight-loss attempts.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.